Navigation Links
Fight against hay fever and other allergies helped by new immune system discovery
Date:12/26/2007

A mechanism which can lead to hay fever and other allergic reactions, by preventing the immune system from regulating itself properly, has been discovered by scientists. Researchers hope their finding, published today (Thursday 27 December 2007) in the journal PLoS Biology, will allow therapies to be developed that treat allergies by stopping this mechanism.

The new research shows that a gene known as GATA-3 can block the development of regulatory T-cells in the immune system by locking another gene. This gene, FOXP3, is key to regulatory T cells and when it is blocked new regulatory T cells stop being produced.

The scientists, from Imperial College London, the Swiss Institute of Allergy and Asthma Research in Davos, Switzerland, and other international institutions, hope that if they can develop therapies to stop FOXP3 being blocked, they can ensure that regulatory T cells are free to work normally.

Regulatory T cells are believed to be vital for averting allergic reactions in healthy individuals because they keep the other cells in check, suppressing pro-allergic cells known as Th2 cells and stopping the immune system from needlessly attacking the body.

In people with allergies, some types of cells in the immune system, particularly the Th2 cells, wrongly identify a particular allergen, such as pollen, as being dangerous. Whenever the person encounters this allergen again, these cells promote the production of antibodies to attack it, causing an allergic reaction.

Dr Carsten Schmidt-Weber, the principal investigator on the research from the National Heart and Lung Institute at Imperial College London, said: This finding will help us to understand how healthy individuals are able to tolerate allergens and what we need to do to re-induce tolerance in the immune systems of patients with allergies. We hope that we will soon be able to help not only patients suffering from single allergies, but also those with multiple ones - the atopic patients.

The researchers reached their conclusions by analysing the genes related to regulatory T-cells and analysing how they interacted. They confirmed their findings by using mouse models to show that mice which were genetically engineered to express the GATA-3 gene in all T cells showed dramatic defects in the production of regulatory T-cells.

Dr Schmidt-Weber and his colleague Professor Stephen Durham, also from the National Heart and Lung Institute at Imperial College, hope the new findings will eventually lead to new, more effective treatments for hayfever and other allergies, to be used in combination with existing immunotherapies. They hope such treatments could help prevent hay fever and allergic asthma from reaching epidemic proportions.


'/>"/>

Contact: Laura Gallagher
L.Gallagher@imperial.ac.uk
44-020-759-46702
Imperial College London
Source:Eurekalert

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Computers help chemists fight emerging infections
3. Study shines more light on benefit of vitamin D in fighting cancer
4. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
5. HIV Drug Might Fight Cancer
6. ADA Challenges Marylanders to Step Out to Fight Diabetes Epidemic
7. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
8. Drug, Pacemaker Fight Irregular Heartbeat
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. The fight against colorectal cancer
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... BSI and Brenntag Canada have been appointed by Chr. ... of their natural fruits and beverage colorants effective November 1, 2016. ... our Life Sciences product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... TCS was previously a subsidiary of Chiltern International and focuses on ...
(Date:12/5/2016)... ... ... The new knee compression sleeves come as a pair which will provide ... lifting and any sport that requires knee compression or protection from the demands ... higher quality knee sleeve performance. Firstly it is made out of premium 7mm thick ...
(Date:12/5/2016)... OH (PRWEB) , ... December 05, 2016 , ... ... engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy of ... in various healthcare settings. , Over the last 60 years, studies have ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response ... and tolerability profile of ropeginterferon alfa-2b versus HU ... ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization ... present this data to the FDA as it seeks approval ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... 3, 2016   Pairnomix, LLC, a genetic research ... recognized by the White House, today announced that findings from ... identification of candidate therapies for a patient with epileptic encephalopathy ... were presented at the 70 th Annual Meeting of ... TX , December 2-6, 2016.  Pairnomix, unique ...
Breaking Medicine Technology: